Patent ID: 8815886
Filing Date: 2014-08-26
Classification: A61K,A61P,C07B,C07D

Abstract:
1. A method of treating a subject having a disease selected from the group consisting of Type I diabetes, Type II diabetes and metabolic syndrome, said method comprising administering to said subject in need of such treatment an effective amount of a crystalline salt of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine selected from the group consisting of: besylate salt having an X-ray power diffraction pattern substantially as shown in camsylate salt having an X-ray power diffraction pattern substantially as shown in esylate salt having an X-ray power diffraction pattern substantially as shown in HBr salt having an X-ray power diffraction pattern substantially as shown in HCl salt having an X-ray power diffraction pattern substantially as shown in HCl salt having an X-ray power diffraction pattern having peaks at degrees 2-theta diffraction angles of about 8.8, 10.8, 16.1, 17.4, 20.4, 20.9, 21.5, 21.7, 26.6, and 28.1, HCl salt having an X-ray power diffraction pattern having peaks at degrees 2-theta diffraction angles of about 7.8, 10.1, 12.5, 18.4, 19.0, 20.8, 23.0, and 23.5, mesylate salt having an X-ray power diffraction pattern substantially as shown in sulfate salt having an X-ray power diffraction pattern substantially as shown in tosylate salt having an X-ray power diffraction pattern substantially as shown in